Zenagamtide Phase 2 Diabetes Results at ADA 2026

Novo Nordisk presented positive Phase 2 clinical data for once-weekly zenagamtide.

Managing type 2 diabetes and body weight could soon get much easier. On June 5, 2026, Novo Nordisk presented exciting Phase 2 results for zenagamtide (formerly known as amycretin or NN9487) at the American Diabetes Association (ADA) 86th Scientific Sessions. This experimental drug represents a new class of metabolic treatments designed to manage both blood sugar and weight. The 36-week study showed significant reductions in blood sugar levels (HbA1c) and body weight in adults.

Weekly injections of zenagamtide led to impressive, dose-dependent improvements in health markers. The trial successfully met its targets while showing a safety profile similar to existing GLP-1 medications. Following these positive results, Novo Nordisk plans to start Phase 3 trials in the second half of 2026. This milestone builds upon the company's existing cardiometabolic portfolio, which features well-known options like semaglutide.

What Is Zenagamtide and How Does Its Dual-Action Mechanism Work?

Zenagamtide is a first-of-its-kind, long-acting weekly injection that acts as a dual hormone mimic, targeting both GLP-1 and amylin receptors. While traditional treatments focus only on one metabolic pathway, this drug combines two complementary mechanisms in a single molecule. Researchers designed this dual action to target hunger and blood sugar regulation more effectively. This synergistic approach could offer patients a more powerful tool for managing type 2 diabetes and weight.

The GLP-1 portion of zenagamtide mimics the natural gut hormone that your body releases after eating. This hormone signals your pancreas to release insulin, helps reduce sugar production in the liver, and stabilizes blood glucose after meals. Currently, patients can access established semaglutide treatment programs, which use this single GLP-1 pathway to help control blood sugar and support weight loss. Zenagamtide aims to build on this success by adding a second target.

The second target, amylin, is a hormone that works alongside insulin to control hunger and blood sugar. By activating the amylin receptor, zenagamtide enhances the body's natural satiety signals to help you feel full. Interestingly, May 2026 data suggests that zenagamtide works directly on brain satiety pathways rather than simply slowing stomach emptying. This distinct central nervous system action may explain its powerful blood sugar and weight benefits.

What Did the Phase 2 Clinical Trial Design Evaluate?

The Phase 2 study was a randomized, double-blind trial designed to find the safest and most effective dose of zenagamtide. Researchers evaluated six different weekly doses compared to a placebo in 262 adults with type 2 diabetes. All participants had blood sugar levels (HbA1c) between 7.0% and 10.0% that were not fully controlled by metformin or other common diabetes medications. Testing a wide range of doses helped researchers find the optimal balance between efficacy and tolerability.

Participants received weekly injections ranging from a low 0.4 mg dose up to a maximum 40 mg dose of zenagamtide, or a placebo. Over a 36-week treatment period, doctors monitored blood sugar, weight loss, and side effects. This careful testing helped identify the best therapeutic window to maximize health improvements. Understanding this dose response is a critical step in clinical development.

The trial included a diverse group of adults representing the real-world type 2 diabetes population. All patients continued taking metformin as a background treatment during the study. This setup allowed researchers to isolate the exact impact of zenagamtide on blood sugar and weight. Designing trials this way ensures the results are directly meaningful to patients seeking effective add-on therapies.

How Efficacious Was Zenagamtide for Blood Sugar Control and Weight Loss?

Zenagamtide achieved outstanding results by significantly lowering blood sugar across all active doses. Patients on the highest 40 mg dose experienced an average 1.71% reduction in HbA1c by week 36. Impressively, 89.1% of patients in this group successfully brought their overall blood sugar below the clinical target of 7.0%. These results highlight the dual-action drug's ability to help patients gain control over their diabetes.

Patients also experienced substantial, dose-dependent weight loss during the study. On the 40 mg dose, patients lost an average of 14.6% of their body weight, compared to just 2.1% in the placebo group. Excitingly, weight loss did not plateau or flatten out by the end of the 36 weeks. This continuous downward trend suggests that longer-term treatment could help patients lose even more weight over time.

Targeting GLP-1 and amylin together could provide superior results compared to single-hormone drugs. If you are exploring advanced treatments, you might also look at tirzepatide options, which target GLP-1 and GIP receptors. The rise of zenagamtide shows that the amylin pathway is another highly effective target for metabolic health. Discussing these different metabolic pathways with your doctor can help you find the right approach for your body.

What Safety and Tolerability Patterns Emerged in the Phase 2 Results?

Like other GLP-1 therapies, zenagamtide's main side effects were gastrointestinal. Some patients experienced temporary nausea, vomiting, diarrhea, or constipation during the study. Fortunately, the majority of these symptoms were mild to moderate. They typically occurred as patients started the drug or increased their dose, and then resolved as their bodies adjusted.

Crucially, the trial reported low rates of serious side effects and no unexpected safety concerns. Hypoglycemia, or dangerously low blood sugar, was extremely rare during the 36-week period. The overall rate of patients stopping treatment due to side effects was very low and comparable to existing therapies. This shows that the gradual dosing schedule successfully helped patients stay on track with their treatment.

While zenagamtide undergoes further testing, several established, fully approved therapies are available right now. If you want to explore these options, you can check if you qualify online to connect with a licensed medical professional. You can also view current pricing details to understand the financial aspects of these treatments. Working with a healthcare provider remains the safest way to find an approved metabolic therapy that fits your needs.

What Lies Ahead for Novo Nordisk's Zenagamtide R&D Pipeline?

Novo Nordisk will progress zenagamtide into Phase 3 clinical trials in the second half of 2026. This next phase of testing will include thousands of patients over longer periods to confirm the drug's safety. Researchers will also evaluate how the therapy affects long-term heart health and diabetes complications. These extensive trials are the final step required before seeking FDA approval.

In addition to the weekly injection, researchers are actively developing an oral version of zenagamtide. Having both a pill and an injection option gives patients greater choice and flexibility in their care. A daily pill could offer a highly convenient, needle-free option for managing diabetes and weight. This expansion of treatment options represents a major focus for Novo Nordisk's metabolic pipeline.

Zenagamtide is a key part of Novo Nordisk's pipeline, alongside other combination treatments like CagriSema. These pipeline advancements highlight the rapid pace of metabolic research today. Patients and healthcare providers will watch future clinical readouts closely to see how these therapies perform. For now, we continue to see exciting progress in the development of highly effective metabolic treatments.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.